Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sanjay Popat

Showing results (91-100 of 272) with videos related to

Pageof 28
Sort By:
Medical Oncology (Northwood, London, England)|December 29, 2011
Chemotherapy-induced bowel obstruction in small cell lung cancer: a case reportJermaine I G Coward, Nicola-Louise Ding, Roger Feakins, et al.
Clinical Epidemiology|July 22, 2025
Mortality Outcomes in People with Lung Cancer with and without Type2 Diabetes: A Cohort Study in EnglandEseosa Grace Igbinosa, Bodini Dharmasekara, Jennifer K Quint, et al.
Future Oncology (London, England)|December 6, 2014
Nintedanib plus docetaxel as second-line therapy in patients with non-small-cell lung cancer: a network meta-analysisSanjay Popat, Anders Mellemgaard, Kyle Fahrbach, et al.
Lung Cancer (Amsterdam, Netherlands)|March 19, 2013
A rare case of squamous cell carcinoma of the lung harbouring ALK and BRAF activating mutationsDoraid Alrifai, Sanjay Popat, Merina Ahmed, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 14, 2010
Refining the diagnosis and EGFR status of non-small cell lung carcinoma in biopsy and cytologic material, using a panel of mucin staining, TTF-1, cytokeratin 5/6, and P63, and EGFR mutation analysisAndrew G Nicholson, David Gonzalez, Pallav Shah, et al.
Journal of Comparative Effectiveness Research|January 11, 2024
Quantitative bias analysis for external control arms using real-world data in clinical trials: a primer for clinical researchersKristian Thorlund, Stephen Duffield, Sanjay Popat, et al.
JTCVS Open|July 9, 2025
Physician specialty shapes hypothetical self-treatment choices for locally advanced non-small cell lung cancer: Is the "best" option subjective?Mara B Antonoff, Corinne Faivre-Finn, Patrick M Forde, et al.
BMC Cancer|April 27, 2013
Early pneumothorax as a feature of response to crizotinib therapy in a patient with ALK rearranged lung adenocarcinomaSpyridon Gennatas, Susana J Stanway, Robert Thomas, et al.
Plos One|July 7, 2022
Splenic volume as a predictor of treatment response in patients with non-small cell lung cancer receiving immunotherapyFrancesca Castagnoli, Simon Doran, Jason Lunn, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|January 25, 2023
Hyperglycaemia following immune checkpoint inhibitor therapy-Incidence, aetiology and assessmentKaenat Mulla, Sheima Farag, Benedict Moore, et al.
Pageof 28

Showing results (91-100 of 272) with videos related to

Sort By:
Pageof 28
Medical Oncology (Northwood, London, England)|December 29, 2011
Chemotherapy-induced bowel obstruction in small cell lung cancer: a case reportJermaine I G Coward, Nicola-Louise Ding, Roger Feakins, et al.
Clinical Epidemiology|July 22, 2025
Mortality Outcomes in People with Lung Cancer with and without Type2 Diabetes: A Cohort Study in EnglandEseosa Grace Igbinosa, Bodini Dharmasekara, Jennifer K Quint, et al.
Future Oncology (London, England)|December 6, 2014
Nintedanib plus docetaxel as second-line therapy in patients with non-small-cell lung cancer: a network meta-analysisSanjay Popat, Anders Mellemgaard, Kyle Fahrbach, et al.
Lung Cancer (Amsterdam, Netherlands)|March 19, 2013
A rare case of squamous cell carcinoma of the lung harbouring ALK and BRAF activating mutationsDoraid Alrifai, Sanjay Popat, Merina Ahmed, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 14, 2010
Refining the diagnosis and EGFR status of non-small cell lung carcinoma in biopsy and cytologic material, using a panel of mucin staining, TTF-1, cytokeratin 5/6, and P63, and EGFR mutation analysisAndrew G Nicholson, David Gonzalez, Pallav Shah, et al.
Journal of Comparative Effectiveness Research|January 11, 2024
Quantitative bias analysis for external control arms using real-world data in clinical trials: a primer for clinical researchersKristian Thorlund, Stephen Duffield, Sanjay Popat, et al.
JTCVS Open|July 9, 2025
Physician specialty shapes hypothetical self-treatment choices for locally advanced non-small cell lung cancer: Is the "best" option subjective?Mara B Antonoff, Corinne Faivre-Finn, Patrick M Forde, et al.
BMC Cancer|April 27, 2013
Early pneumothorax as a feature of response to crizotinib therapy in a patient with ALK rearranged lung adenocarcinomaSpyridon Gennatas, Susana J Stanway, Robert Thomas, et al.
Plos One|July 7, 2022
Splenic volume as a predictor of treatment response in patients with non-small cell lung cancer receiving immunotherapyFrancesca Castagnoli, Simon Doran, Jason Lunn, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|January 25, 2023
Hyperglycaemia following immune checkpoint inhibitor therapy-Incidence, aetiology and assessmentKaenat Mulla, Sheima Farag, Benedict Moore, et al.
Pageof 28